-

Bacainn Therapeutics’ Ashley Mansell to Present on BT032, a Novel First-in-Class NLRP1 and NLRP3 Inhibitor, at the 3rd Inflammasome Therapeutics Digital Summit

CONCORD, Mass.--(BUSINESS WIRE)--Bacainn Therapeutics, Inc., a biotechnology company focused on developing novel therapies that target the innate immune system to address uncontrolled inflammation, today announced that Ashley Mansell, PhD, Senior Director of Research & Development, Bacainn Therapeutics & Principal Investigator, Hudson Institute of Medical Research, will present at the 3rd Inflammasome Therapeutics Summit being held virtually on November 16 – 18. Dr. Mansell’s presentation will focus on the discovery and characterization of BT032, a novel dual NLRP1 and NLRP3 inhibitor, and its potential application for the treatment of pulmonary inflammation.

Details of Presentation:

MEETING: Inflammasome Therapeutics Summit

SESSION: Stream B - Advances in Pre-Clinical Models & Proof-of-Concept Trials

TITLE: BT032: A Novel NLRP1 & NLRP3 Inhibitor to Treat Pulmonary Inflammation

TIMING: Wednesday, November 17, 2021, 11:30 am ET – Digital Event

About Bacainn Therapeutics

Bacainn Therapeutics is developing novel therapies that target the innate immune system to address uncontrolled inflammation. The company was founded on novel and extensive insights into neutrophil and inflammasome biology which allow for potentially new and bold approaches to treating inflammatory diseases. Bacainn’s lead asset, BT051, is currently in clinical development for the treatment of moderate to severe ulcerative colitis. Identification of proprietary compounds that simultaneously block NLRP1 and NLRP3 inflammasomes led to the breakthrough discovery of BT032, which is being investigated for therapeutic application in respiratory and other inflammasome-mediated diseases. Founded in 2017, Bacainn is funded by Morningside Ventures. For more information, https://bacainntherapeutics.com.

Contacts

Wendy Gabel
Kendall Investor Relations
wgabel@kendallir.com

Industry:

Bacainn Therapeutics, Inc.

Release Versions
English

Contacts

Wendy Gabel
Kendall Investor Relations
wgabel@kendallir.com

More News From Bacainn Therapeutics, Inc.

Bacainn Therapeutics Presents at ECCO ‘21 Results from Phase 1 Study that Shows BT051, an Oral, Locally-Acting Inhibitor of Neutrophil Trafficking and Activity, Is Safe and Well-Tolerated in Healthy Adults

CONCORD, Mass.--(BUSINESS WIRE)--Bacainn Therapeutics, Inc., a biotechnology company focused on developing novel therapies that target the innate immune system to address uncontrolled inflammation, today presented results at the European Crohn’s and Colitis Organisation’s 2021 Virtual Congress from a Phase 1 study that showed its lead asset BT051 was safe and well-tolerated in healthy adults. BT051 is an oral, locally-acting inhibitor of neutrophil trafficking and activation and is in clinical...

Bacainn Therapeutics Reports Positive Topline Results from Phase 1 Study of BT051, a Novel Therapeutic Approach to Treat Inflammatory Diseases Such As Ulcerative Colitis

CONCORD, Mass.--(BUSINESS WIRE)--Bacainn Therapeutics, Inc., a Company developing novel therapies to address uncontrolled inflammation, today announced the successful completion of the company’s Phase 1, first-in-human clinical trial of BT051, a novel, orally administered, gut-selective inhibitor of migration and activation of neutrophils. During active flares of ulcerative colitis, neutrophils migrate into the submucosa and lumen of the colon where they contribute to tissue damage by releasing...

Bacainn Therapeutics Announces IND Clearance for BT051 and Initiation of Phase 1 Clinical Trial, Bacainn’s First Clinical Candidate for the Treatment of Ulcerative Colitis

CONCORD, Mass.--(BUSINESS WIRE)--Bacainn Therapeutics, Inc., a Company developing novel therapies to address uncontrolled inflammation, announced today FDA’s Clearance of the IND for BT051, and initiation of a Phase 1 Clinical Trial with patient dosing expected in the coming months. BT051 is a first-in-class approach to modulating the migration and activation of specific innate immune cells (neutrophils) and is being developed to treat various acute medical conditions including ulcerative colit...
Back to Newsroom